Chemical Exchange Saturation Transfer (CEST) MRI for the Characterization Small Renal Masses

用于表征小肾脏肿块的化学交换饱和转移 (CEST) MRI

基本信息

批准号：
10611440
负责人：
IVAN E DIMITROV
金额：
$ 46.23万
依托单位：
UT SOUTHWESTERN MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-05-17 至 2026-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10611440
关键词：
Abdomen Ablation Academia Acceleration Accounting Address Adopted Algorithms Benign Biological Markers Biopsy Chemicals Clear cell renal cell carcinoma Clinical Clinical Assessment Tool Clinical Research Collaborations Complication Contrast Media Deposition Detection Development Diagnosis Early Diagnosis Elements Evaluation Exposure to Fatty acid glycerol esters Glycogen Goals Histologic Histology Histopathology Human Image Imaging Device Imaging technology Immunohistochemistry Incidence Indolent Industry Injections Kidney Knowledge Magnetic Resonance Imaging Malignant - descriptor Malignant Neoplasms Maps Measurement Medical center Metabolic Methodology Methods Molecular Morbidity - disease rate Motion North America Oncology Operative Surgical Procedures Oxyphilic Adenoma Patient-Focused Outcomes Patients Perfusion Predictive Value Procedures Prognosis Protocols documentation Publications Renal Cell Carcinoma Renal Mass Renal carcinoma Reporting Research Research Personnel Resolution Role Scientist Signal Transduction Specialized Program of Research Excellence Spectrum Analysis Stratification Structure System Techniques Technology Technology Transfer Texas Tissues Translating Translations Universities Woman anatomic imaging breast lesion clinical center clinical translation cohort imaging modality improved in vivo industry partner kidney imaging men mortality neuro-oncology non-invasive imaging novel overtreatment preclinical study predictive marker programs psychologic recruit respiratory risk stratification soft tissue success tool treatment effect tumor tumor microenvironment virtual biopsy

项目摘要

Project Summary An Academic-Industrial partnership between scientists and clinicians at the University of Texas Southwestern (UTSW) Medical Center and Philips Research Hamburg and Philips North America (Philips) has been formed with the purpose of translating the novel molecular MR imaging method, Chemical Exchange Saturation Transfer (CEST), into a clinical tool for the assessment of Small Renal Masses (SRMs). CEST has already demonstrated feasibility in neurooncology applications. The management of SRMs is challenging because a substantial number of them are benign or indolent malignant tumors, leading to patient exposure to unnecessary morbidity from biopsies and surgery. Non-invasive distinction between benign/indolent tumors and aggressive tumors would allow for better risk stratification and patient management. While novel, CEST has already been adopted by certain clinical centers for assessment in neuro oncology. Recently, our group demonstrated the promise of CEST to the characterization of breast lesions. Here, we propose to broaden the application of CEST to renal oncology by addressing the inherent challenges of application of CEST in the abdomen and by optimizing CEST in patients with SRMs. Our hypothesis is that technical development of CEST-MRI allows observation of aggressive tumor microenvironment in SRM. Our goal is to advance CEST methodology to become a part of comprehensive SRM evaluation protocol. The goals of the project will be achieved via the following Specific Aims: Aim 1: To develop and optimize CEST methodology for SRMs on 3T human MRI system. This is technical development Aim, where we will evaluate several approaches addressing major issues associated with translation of CEST to kidney oncology applications: (i) improved resolution and fat separation, (ii) acceleration of acquisition using pseudo-cartesian and undersampled algorithms,(iii) motion correction and (iv) advanced Z-spectrum analysis methods. Aim 2: To evaluate the optimized CEST-MRI as a predictive biomarker of SRM hystology. The Aim's focus in on the translation of the CEST technology to SRM patients: (i) evaluation of the optimized in a group of SRM patients: (ii) correlation of the CEST-MRI measurements with histopathology results and correlation of CEST-MRI with glycogen deposition.

项目摘要德克萨斯大学西南大学科学家与临床医生之间的学术工业合作伙伴关系（UTSW）医疗中心和飞利浦研究汉堡和飞利浦北美（飞利浦）已成立为了翻译新型分子MR成像方法，化学交换饱和转移（CEST），成为评估小肾脏（SRM）的临床工具。西斯已经在神经学应用中证明了可行性。 SRM的管理很具有挑战性，因为其中大量是良性或懒惰的恶性肿瘤，导致患者暴露于活检和手术的不必要发病率。良性/懒惰肿瘤之间的非侵入性区别侵略性肿瘤将允许更好的风险分层和患者管理。虽然新颖，cest 某些临床中心已经采用了神经肿瘤学评估。最近，我们的小组证明了对乳房病变表征的诺言的希望。在这里，我们建议扩大通过解决CEST在肾脏肿瘤学上的应用到肾脏肿瘤学的应用腹部和通过优化SRMS患者的CEST。我们的假设是CEST-MRI的技术发展允许观察侵袭性肿瘤 SRM中的微环境。我们的目标是推进CEST方法论成为综合SRM的一部分评估协议。该项目的目标将通过以下特定目的实现：目标1：在3T人MRI系统上开发和优化SRMS的CEST方法论。这是技术发展目标，我们将评估几种解决重大问题的方法与CEST转换为肾脏肿瘤的应用有关：（i）改善分辨率和脂肪分离，（ii）使用伪卡车和不采样算法加速获取，（iii）运动校正和（iv）高级Z光谱分析方法。 AIM 2：评估优化的CEST-MRI作为SRM Hestology的预测生物标志物。该目标的重点是将CEST技术转换给SRM患者：（i）评估优化在一组SRM患者中：（ii）CEST-MRI测量与组织病理学结果和 CEST-MRI与糖原沉积的相关性。